ALNA - Allena Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
6.35
-0.25 (-3.79%)
At close: 4:00PM EDT

6.35 0.00 (0.00%)
After hours: 4:00PM EDT

Stock chart is not supported by your current browser
Previous Close6.60
Open6.53
Bid6.23 x 800
Ask6.94 x 800
Day's Range6.31 - 6.53
52 Week Range4.80 - 17.26
Volume8,467
Avg. Volume40,187
Market Cap132.175M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-1.72
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est30.43
Trade prices are not sourced from all markets
  • Investors Who Bought Allena Pharmaceuticals (NASDAQ:ALNA) Shares A Year Ago Are Now Down 52%
    Simply Wall St.yesterday

    Investors Who Bought Allena Pharmaceuticals (NASDAQ:ALNA) Shares A Year Ago Are Now Down 52%

    Taking the occasional loss comes part and parcel with investing on the stock market. And unfortunately for Allena Pharmaceuticals, Inc. (NASDAQ:ALNA) shareholders, the stock is a lot lower today than it was a year ago. The sh...

  • GlobeNewswireyesterday

    Allena Pharmaceuticals Appoints Allene Diaz to its Board of Directors

    Allena Pharmaceuticals, Inc. (ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today announced the appointment of Allene Diaz to its Board of Directors. “We are pleased to welcome Allene to our Board of Directors,” said Louis Brenner, M.D., President and Chief Executive Officer of Allena Pharmaceuticals. “Allene joins our team at an opportune time, as we advance our ongoing Phase 3 URIROX™ program and make progress in our quest to deliver the first therapeutic for patients with enteric hyperoxaluria.

  • GlobeNewswire22 days ago

    Allena Pharmaceuticals Announces Agreement with Duke Clinical Research Institute for URIROX-2 Pivotal Phase 3 Trial

    Allena Pharmaceuticals, Inc. (ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today announced an agreement with the Duke Clinical Research Institute (DCRI), a leading academic research institute within Duke University School of Medicine, to support the URIROX-2 Phase 3 clinical trial of reloxaliase in enteric hyperoxaluria. DCRI will establish and lead an Academic Coordinating Center (ACC) for Allena’s URIROX-2, one of two ongoing pivotal Phase 3 clinical trials evaluating the safety and efficacy of reloxaliase as a novel therapy for patients with enteric hyperoxaluria.

  • GlobeNewswirelast month

    Allena Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update

    Allena Pharmaceuticals, Inc. (ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today reported financial results for the fourth quarter and full year ended December 31, 2018 and provided a business update. “We have made significant progress in our clinical development programs over the last few months, including securing alignment with the FDA on our strategy to pursue accelerated approval for reloxaliase in enteric hyperoxaluria, initiating URIROX-2, our second pivotal Phase 3 trial, and advancing enrollment in both URIROX-1, our first pivotal Phase 3 trial, and in Study 206, our Phase 2 basket study of reloxaliase in patients with primary or enteric hyperoxaluria and advanced chronic kidney disease,” said Louis Brenner, M.D., Chief Executive Officer of Allena Pharmaceuticals.

  • GlobeNewswirelast month

    Allena Pharmaceuticals, Inc. to Present at 39th Annual Cowen & Co. Health Care Conference

    NEWTON, Mass., March 05, 2019 -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing.

  • GlobeNewswire3 months ago

    Allena Pharmaceuticals Announces Appointment of Louis Brenner, M.D. as Chief Executive Officer and Confirms Key Milestones for 2019

    Allena Pharmaceuticals, Inc. (ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today announced that Louis Brenner, M.D., President and Chief Operating Officer at Allena, will be promoted to Chief Executive Officer and appointed to the Board of Directors effective February 1, 2019.  Dr.  Brenner will succeed Alexey Margolin, Ph.D. as Chief Executive Officer.  Dr.  Margolin, who co-founded Allena in 2011, will transition to Chairman of the Board effective February 1, 2019.  He will continue advising the company in this new role. Louis Brenner, M.D. has served as Chief Operating Officer of Allena since April 2015 and as President since February 2017.

  • GlobeNewswire3 months ago

    Allena Pharmaceuticals Achieves Alignment with FDA on Phase 3 Program and Accelerated Approval Pathway for Reloxaliase in Enteric Hyperoxaluria

    Allena’s URIROX program consists of two pivotal Phase 3 clinical trials, URIROX-1 and URIROX-2, which are designed to evaluate the safety and efficacy of reloxaliase in patients with enteric hyperoxaluria. URIROX-1 is currently enrolling patients, and Allena initiated URIROX-2 in the fourth quarter of 2018.

  • Do Hedge Funds Love Allena Pharmaceuticals, Inc. (ALNA)?
    Insider Monkey4 months ago

    Do Hedge Funds Love Allena Pharmaceuticals, Inc. (ALNA)?

    The Insider Monkey team has completed processing the quarterly 13F filings for the September quarter submitted by the hedge funds and other money managers included in our extensive database. Most hedge fund investors endured a torrid quarter, which certainly propelled them to adjust their equity holdings so as to maintain the desired risk profile. As […]

  • GlobeNewswire5 months ago

    Recent Analysis Shows Arcimoto, ADOMANI, Lipocine, Aileron Therapeutics, Allena Pharmaceuticals, and Perma-Fix Environmental Services Market Influences — Renewed Outlook, Key Drivers of Growth

    NEW YORK, Nov. 19, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • GlobeNewswire5 months ago

    Allena Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Business Update

    Allena Pharmaceuticals, Inc. (ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today reported financial results for the third quarter ended September 30, 2018 and also provided a business update. “As new research emerges on oxalate’s damaging effects on the kidneys, we are encouraged by the growing awareness of enteric hyperoxaluria and widespread focus on addressing the significant burden of kidney stone disease and kidney damage that it causes.

  • GlobeNewswire5 months ago

    Allena Pharmaceuticals to Present at Upcoming Investor Conferences in November

    NEWTON, Mass., Nov. 06, 2018 -- Allena Pharmaceuticals, Inc. (NASDAQ:ALNA), a late-stage biopharmaceutical company dedicated to developing and commercializing first-in-class,.

  • Allena Pharmaceuticals Enters Oversold Territory
    Zacks9 months ago

    Allena Pharmaceuticals Enters Oversold Territory

    Allena Pharmaceuticals has been on a bit of a cold streak lately but there might be light at the end of the tunnel for this overlooked stock.

  • Allena Pharmaceuticals Inc (NASDAQ:ALNA): Are Analysts Bull Or Bear?
    Simply Wall St.last year

    Allena Pharmaceuticals Inc (NASDAQ:ALNA): Are Analysts Bull Or Bear?

    The most recent earnings announcement Allena Pharmaceuticals Inc’s (NASDAQ:ALNA) released in December 2017 confirmed company earnings became less negative compared to the previous year’s level – great news for investorsRead More...